Worth Venture Partners, LLC Aveo Pharmaceuticals, Inc. Transaction History

Worth Venture Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.48 - $14.97 $4.36 Million - $7.7 Million	-514,101 Reduced 75.05%	170,925 $2.56 Million
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $207,620 - $273,895	-31,410 Reduced 4.38%	685,026 $5.64 Million
Q2 2022 Aug 15, 2022	BUY	$3.51 - $6.67 $39,599 - $75,250	11,282 Added 1.6%	716,436 $4.74 Million
Q1 2022 May 16, 2022	BUY	$3.15 - $6.01 $377,955 - $721,115	119,986 Added 20.5%	705,154 $3.94 Million
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $613,470 - $967,949	130,804 Added 28.79%	585,168 $2.74 Million
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $2.33 Million - $3.13 Million	454,364 New	454,364 $2.81 Million

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.